Allergen injection immunotherapy for seasonal allergic rhinitis (Q24243115)

6

object named as

Stephen Durham

0 references

Moises A Calderon

1

object named as

Moises A Calderon

0 references

author name string

Bernadette Alves

2

0 references

Mikila Jacobson

3

0 references

Brian Hurwitz

Cochrane Database of Systematic Reviews

4

0 references

publication date

24 January 2007

0 references

published in

0 references

cites work

Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Polyethylene glycol-modified ragweed pollen extract in rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Clinical and immunologic evaluation of glutaraldehyde-modified tyrosine-adsorbed short ragweed extract: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Is homeopathic 'immunotherapy' effective? A double-blind, placebo-controlled trial with the isopathic remedy Betula 30c for patients with birch pollen allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Safety of sublingual-swallow immunotherapy in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Poylmerized whole ragweed: an improved method of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Retrospective assessment of seasonal allergic symptoms: over-rating but useful.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The role of ragweed pollen in autumnal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Allergen injection therapy with glutaraldehyde-modified--ragweed pollen-tyrosine adsorbate. A double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Ragweed immunotherapy in adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy decreases the number of mast cells in the skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A single dose desensitization for summer hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Comparison of two dosages of ragweed extract in the treatment of pollenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Occupational rhinoconjunctivitis and food allergy because of aniseed sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Allergenicity, immunogenicity, and safety of immunotherapy with various molecular weight ranges of polymerized ragweed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Tolerance and short-term effect of a cluster schedule with pollen-extracts quantified in mass-units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The upper airway response to pollen is enhanced by exposure to combustion particulates: a pilot human experimental challenge study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A multi-institutional trial of polymerized whole ragweed for immunotherapy of ragweed allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Does specific immunotherapy injection cause an increase in bronchial reactivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Hyposensitization in childhood hay fever. A comparison of refined and whole timothy extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunologic and cellular changes accompanying the therapy of pollen allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Lack of suppression of IgE production by recombinant interferon gamma: a controlled trial in patients with allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A Double-Blind Study of the Effectiveness and Specificity of Injection Therapy in Ragweed Hay Fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Clinical and immunological studies of timothy antigen D immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Vaccination with genetically engineered allergens prevents progression of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy of hay fever with ragweed antigen E: Comparisons with whole pollen extract and placebos

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A rational approach to desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Trials of alum-precipitated pollen extracts in the treatment of hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunologic responses to conjugates of antigen E in patients with ragweed hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Anti-IgG Antibodies during Immunotherapy with Purified Grass Pollen Extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Specific IgE response toward allergenic molecules during perennial hyposensitization: a three-year prospective double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy for mountain cedar pollinosis. A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Orally Administered Grass Pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever. Use of allergenically bioequivalent doses by parallel line bioassay to evaluate comparative safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Seasonal increase of spontaneous histamine release in washed leucocytes from rhinitis patients sensitive to grass pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Asthma and allergic rhinitis in Swedish conscripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The major allergen content of allergenic preparations reflect their biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

ABC of allergies. Summer hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Burden of allergic disease in the UK: secondary analyses of national databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

ABC of allergies. The epidemiology of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The safety of allergenic immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Survey of fatalities from skin testing and immunotherapy 1985-1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Mechanisms of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

The Effect of Japanese Cedar-specific Immunotherapy on Cytokine Production in Peripheral Blood Mononuclear Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

Effect of allergen specific immunotherapy (IT) on natural killer cell activity (NK), IgE, IFN-gamma levels and clinical response in patients with allergic rhinitis and asthma

21 January 2018

1 reference

12 December 2020

Hyposensitization. Comparing a purified (refined) allergen preparation and a crude aqueous extract from timothy pollen

1 reference

12 December 2020

Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance.

1 reference

12 December 2020

The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children

1 reference

12 December 2020

A double-blind study of the discontinuation of ragweed immunotherapy

1 reference

12 December 2020

Clinical study of methods for determining immunoglobulin E in allergy

1 reference

12 December 2020

Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis

1 reference

12 December 2020

A single dose desensitization for summer hay fever. Results of a double blind study-1988

1 reference

12 December 2020

Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens

1 reference

12 December 2020

Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial

1 reference

12 December 2020

Allergen specific IgG subclass antibody response in hyposensitization with Dermatophagoides pteronyssinus extract

1 reference

12 December 2020

Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study

1 reference

12 December 2020

Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial

1 reference

12 December 2020

Characteristics of hay fever during pollen season with regard to the influence of specific immunotherapy. I. Clinical course and biochemical changes in nasal lavage

1 reference

12 December 2020

Rush immunotherapy with a standardized Bermuda grass pollen extract

1 reference

12 December 2020

The effect of 6-mercaptopurine on antibody production in atopic individuals

1 reference

12 December 2020

Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment

1 reference

12 December 2020

Hyposensitization in hay fever with grass pollen extracts: a three-year study comparing a dialysed alum adsorbed extract with allpyral.

1 reference

12 December 2020

Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study

1 reference

12 December 2020

Clinical, biochemical and immunological effectiveness of diacetyl-splenopentin (BCH 069) in hay fever.

1 reference

12 December 2020

Phase-I study of diacetyl-splenopentin (BCH 069)

1 reference

12 December 2020

Correlation of type specific fluorescent antibodies to ragweed with symptomatology: double-blind study

1 reference

12 December 2020

A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy

1 reference

12 December 2020

Clinical evaluation of hyposensitization in allergic rhinitis: comparison of the results obtained with three different extracts. Material from a 3-year study

1 reference

12 December 2020

A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis

1 reference

12 December 2020

Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses in children and to Parietaria in adult patients

1 reference

12 December 2020

[Results of specific immunotherapy with Allergovit in patients with pollen allergy]

1 reference

12 December 2020

Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study

1 reference

12 December 2020

Allergen-specific immunotherapy in allergic rhinitis

1 reference

12 December 2020

Preseasonal specific immunotherapy with modified Phleum pratense allergenic extracts: tolerability and effects

1 reference

12 December 2020

Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure

1 reference

12 December 2020

Seasonal versus perennial immunotherapy: evaluation after three years of treatment

1 reference

12 December 2020

[Desensitization results in pollen allergic patients with allpyral and aqueous estracts]

1 reference

12 December 2020

Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis

1 reference

12 December 2020

Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals

1 reference

12 December 2020

Pollinosis. II. Specific hyposensitization: indications and results of treatment. A study with the allergen preparation Stallergenes-Depot in the pollen season of 1976, 1977 and 1978

1 reference

12 December 2020

Preseasonal specific immunotherapy with modified phleum pratense allergenic extracts: tolerability and effects

1 reference

12 December 2020

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract

1 reference

12 December 2020

Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract

1 reference

12 December 2020

Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response

1 reference

12 December 2020

[Evaluation of soluble components of receptors with weak affinity for IgE (sCD23) in children with pollinosis given specific immunotherapy]

1 reference

12 December 2020

The effect of immune milk as a treatment for ragweed pollinosis

1 reference

12 December 2020

[A modified therapy of hayfever with a depot-preparation (author's transl)]

1 reference

12 December 2020

Changes in cytokine production in vitro during the early phase of birch-pollen immunotherapy

1 reference

12 December 2020

Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis

1 reference

12 December 2020

Allergen-specific low-dose immunotherapy in perennial allergic rhinitis: a double-blind placebo-controlled crossover study.

1 reference

12 December 2020

[Reduced allergen immunotherapy of grass pollinosis (author's transl)]

1 reference

12 December 2020

Effectiveness of Hyposensitization Therapy in Ragweed Hay-Fever in Children

1 reference

12 December 2020

A three year controlled study in children with pollinosis treated with immunotherapy

1 reference

12 December 2020

[Allergen-specific immune therapy in the treatment of asthma]

1 reference

12 December 2020

Mediator release is altered in immunotherapy-treated patients: a 4-year study

1 reference

12 December 2020

[Efficacy and tolerance of allergenic extracts Allergovit and Novo-Helisen depot in immunotherapy of allergic diseases]

1 reference

12 December 2020

Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology

1 reference

12 December 2020

Effect of immunotherapy on eosinophil activation in pollen sensitive children.

1 reference

12 December 2020

A multicenter trial of immunotherapy with alginate--conjugated grass pollen extract

1 reference

12 December 2020

Sublingual immunotherapy for allergic rhinitis

1 reference

12 December 2020

Measurement of serum levels of eosinophil cationic protein to monitor patients with seasonal respiratory allergy induced by Parietaria pollen (treated and untreated with specific immunotherapy)

1 reference

12 December 2020

[Hyposensitization in pollinosis. Results of a 3-year controlled study with 2 depot-allergoid grass pollen extracts: aluminum hydroxide-adsorbed allergoid and tyrosine-adsorbed allergoid]

1 reference

12 December 2020

Allergic rhinitis to ragweed pollen. II. Modulation of histamine-releasing factor production by specific immunotherapy

1 reference

12 December 2020

The effect of immunotherapy on the serum levels of eosinophil cationic protein in seasonal allergic rhinitis

1 reference

12 December 2020

Development of the allergy outcome survey for allergic rhinitis

1 reference

12 December 2020

Pollen immunotherapy inhibits T helper 1 and 2 cell responses, but suppression of T helper 2 cell response is a more important mechanism related to the clinical efficacy

1 reference

12 December 2020

Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed parietaria pollen extract over a period of three years in monosensitive patients

1 reference

12 December 2020

The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST.

1 reference

12 December 2020

Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment

1 reference

12 December 2020

A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy

1 reference

12 December 2020

Course of hay fever during the pollen season with respect to the effect of specific immunotherapy. II. Cytologic changes and chemotactic activity in nasal lavage

1 reference

12 December 2020

Immunotherapy with grass pollen major allergens. Immunological results from a prospective 3-year double blind study

1 reference

12 December 2020

Allergen-specific immunotherapy with recombinant grass pollen allergens

1 reference

12 December 2020

Treatment of hay fever by Allerglobuline: a randomized double-blind study

1 reference

12 December 2020

Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome

1 reference

12 December 2020

Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A.

1 reference

12 December 2020

Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils

1 reference

12 December 2020

Suppression of Seasonal Increase in Serum Interleukin-5 is linked to the Clinical Efficacy of Immunotherapy for Seasonal Allergic Rhinitis

1 reference

12 December 2020

[Allergen specific-IgG4 in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy]

1 reference

12 December 2020

Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy.

1 reference

12 December 2020

[Clinical evaluation of Polish allergen extracts Catalet C and Catalet D in patients with pollinosis]

1 reference

12 December 2020

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. II. In vitro results

1 reference

12 December 2020

Suppression of the late cutaneous response by immunotherapy

1 reference

12 December 2020

Epidemiology of allergic rhinitis

1 reference

12 December 2020

Frequency of booster injections of allergoids

1 reference

12 December 2020

Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively

1 reference

12 December 2020

Effect of pollen immunotherapy on food hypersensitivity in children with birch pollinosis

1 reference

12 December 2020

Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study.

1 reference

12 December 2020

The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis

1 reference

12 December 2020

A comparison of the clinical and immunological effects of an alum-precipitated five-grass extract with a conjugated two-grass extract in the desensitization of hay fever

1 reference

12 December 2020

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

12 December 2020

The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis

1 reference

12 December 2020

[Evaluation of effectiveness and safety of three year immunotherapy with mixed grass pollen allergens]

1 reference

12 December 2020

[The influence of a three-year preseasonal specific immunotherapy on selected parameters of allergic inflammation in pollinosis patients]

1 reference

12 December 2020

Placebo-controlled immunotherapy with Cocos nucifera pollen extract

1 reference

12 December 2020

Grass pollen hyposensitization versus placebo therapy. II. Immunotherapy-induced changes in serum IgE and IgG levels

1 reference

12 December 2020

Asthma as a variable in a study of immunotherapy for allergic rhinitis

1 reference

12 December 2020

Polyethylene glycol-modified ragweed extract: comparison of two treatment regimens

1 reference

12 December 2020

Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria)

1 reference

12 December 2020

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma

1 reference

12 December 2020

The effects of allergen-specific immunotherapy on polymorphonuclear leukocyte functions in patients with seasonal allergic rhinitis

1 reference

12 December 2020

Aggressive coseasonal immunotherapy in mountain cedar pollen allergy

1 reference

12 December 2020

Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study

1 reference

12 December 2020

Immunologic responses of pollinosis patients treated with alum-precipitated pyridine ragweed extract

1 reference

12 December 2020

Study on changes in the level of serum IL-4 and soluble CD 23(s-CD23) with immunotherapy in nasal allergy patients

1 reference

12 December 2020

Prevalence of asthma and hay fever in England and Wales

1 reference

12 December 2020

Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody

1 reference

12 December 2020

Immunotherapy of pollinosis: results of a 2-year study with a new allergen preparation (novo-helisen depot) (author's transl)

1 reference

12 December 2020

Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis

1 reference

12 December 2020

Hay fever treated with ACTH gel

1 reference

12 December 2020

PAT--the Preventive Allergy Treatment Study design and preliminary results

1 reference

12 December 2020

Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study

1 reference

12 December 2020

A CONTROLLED TRIAL OF POLLEN ADSORBATE IN THE TREATMENT OF HAY FEVER

1 reference

12 December 2020

Evaluation of the efficacy of immunotherapy with allergovit and catalet in patients with hay fever--multidrug evaluations

1 reference

12 December 2020

Fraction A: a New Immunotherapeutic Approach for Ragweed Pollinosis

1 reference

12 December 2020

Immunotherapy with keyhole lampet hemocyanin-conjugated decapeptide vaccine in cypress pollen allergy

1 reference

12 December 2020

Hay fever symptoms related to immunological findings

1 reference

12 December 2020

A metabolizable adjuvant: clinical trial of grass pollen-tyrosine adsorbate

1 reference

12 December 2020

Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses

1 reference

12 December 2020

Effects of enzyme-potentiated desensitization in the treatment of pollinosis: a double-blind placebo-controlled trial

1 reference

12 December 2020

Hyposensitisation in grass pollen hay fever. A double blind trial of alumn precipitated pollen extract and depot emulsion pollen extract compared with placebo injections

1 reference

12 December 2020

Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis

1 reference

12 December 2020

Specific therapy of pollinosis. Results of desensitization with two different semi-depot allergen extracts (Allpyral and Suspal)

1 reference

12 December 2020

The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions

1 reference

12 December 2020

Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997

1 reference

12 December 2020

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

1 reference

12 December 2020

CSM Update: Desensitising vaccines

1 reference

12 December 2020

Allergen-specific increase in interleukin (IL)-4 and IL-5 secretion from peripheral blood mononuclear cells during birch-pollen immunotherapy

1 reference

12 December 2020

Conditioning rhinitis in allergic humans

1 reference

12 December 2020

Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study

1 reference

12 December 2020

Immunotherapy and allergic inflammation

1 reference

12 December 2020

[Advantages of hyposensitization with a high dose of allergoid in pollen allergy]

1 reference

12 December 2020

Glutaraldehyde-pollen-tyrosine: clinical and immunological studies

1 reference

12 December 2020

Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season

1 reference

12 December 2020

USE OF POISONOAK EXTRACT IN RAGWEED HAY FEVER. A DOUBLE-BLIND STUDY

1 reference

12 December 2020

Incorrect allergy injections: allergists' experiences and recommendations for prevention

1 reference

12 December 2020

The effect of recombinant interleukin-8 on eosinophils' and neutrophils' migration in vivo and in vitro

1 reference

12 December 2020

Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity.

1 reference

12 December 2020

Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study

1 reference

12 December 2020

Emulsion therapy: a three-year study with ragweed pollinosis.

1 reference

12 December 2020

[Short-term immunotherapy--a survey of current studies]

1 reference

12 December 2020

Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response

1 reference

12 December 2020

Side effects during immunotherapy with purified grass pollen extracts

1 reference

12 December 2020

A double-blind, placebo-controlled study of preventive immunotherapy with E.P.D., in the treatment of seasonal allergic disease

1 reference

12 December 2020

Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of

1 reference

12 December 2020

Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology

1 reference

12 December 2020

A comparative trial of hyposensitization in 1973 in the treatment of hay fever using Pollinex and Alavac-P

1 reference

12 December 2020

Comparision of a glutaraldehyde-modified pollen--tyrosine adsorbate with an alum-precipitated pollen vaccine in the treatment of hay fever

1 reference

12 December 2020

A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa

1 reference

12 December 2020

[Immunotherapy, clinical and bronchial response]

1 reference

12 December 2020

Treatment of grass pollenosis with various preparations: eleven-year study.

1 reference

12 December 2020

A multi-allergen ELISA screening method. Comparison with Pharmacia CAP system and Phazet skin prick test

1 reference

12 December 2020

Prevalence and rate of diagnosis of allergic rhinitis in Europe

1 reference

12 December 2020

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects

1 reference

12 December 2020

The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever.

1 reference

12 December 2020

Failure of hyposensitisation in treatment of children with grass-pollen asthma.

1 reference

12 December 2020

Immunotherapy with grass pollen major allergens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

7 January 2021

inferred from DOI database lookup

Position paper: Immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001936.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD001936.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

5112151

5112151

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference